| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 50 | 2021 | 1171 | 4.160 |
Why?
|
| Heart Failure | 45 | 2021 | 2516 | 3.080 |
Why?
|
| Ventricular Dysfunction, Left | 13 | 2013 | 435 | 1.880 |
Why?
|
| Cardiac Catheterization | 4 | 2013 | 687 | 0.890 |
Why?
|
| Milrinone | 3 | 2005 | 33 | 0.750 |
Why?
|
| Natriuretic Peptide, Brain | 5 | 2006 | 343 | 0.740 |
Why?
|
| Rivaroxaban | 1 | 2020 | 59 | 0.720 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 70 | 0.700 |
Why?
|
| Hemodynamics | 7 | 2015 | 935 | 0.680 |
Why?
|
| Ventricular Function, Left | 4 | 2020 | 603 | 0.620 |
Why?
|
| Thrombolytic Therapy | 2 | 2013 | 257 | 0.610 |
Why?
|
| Pyridones | 1 | 2020 | 348 | 0.610 |
Why?
|
| Heart Transplantation | 12 | 2015 | 908 | 0.610 |
Why?
|
| Thrombosis | 4 | 2019 | 781 | 0.600 |
Why?
|
| Prosthesis Design | 9 | 2015 | 749 | 0.600 |
Why?
|
| Intra-Aortic Balloon Pumping | 3 | 2014 | 69 | 0.580 |
Why?
|
| Heart, Artificial | 2 | 2006 | 77 | 0.510 |
Why?
|
| Aorta | 4 | 2014 | 692 | 0.500 |
Why?
|
| Angioplasty, Balloon, Coronary | 3 | 2006 | 314 | 0.500 |
Why?
|
| Antithrombins | 2 | 2013 | 74 | 0.460 |
Why?
|
| Coronary Thrombosis | 1 | 2013 | 44 | 0.450 |
Why?
|
| Mesenteric Vascular Occlusion | 1 | 2013 | 18 | 0.450 |
Why?
|
| Heart Valve Diseases | 2 | 2013 | 193 | 0.410 |
Why?
|
| Pyrazoles | 1 | 2020 | 1471 | 0.400 |
Why?
|
| Myocardial Ischemia | 6 | 2021 | 435 | 0.380 |
Why?
|
| Catheterization | 2 | 2013 | 410 | 0.380 |
Why?
|
| Vascular Diseases | 1 | 2013 | 246 | 0.370 |
Why?
|
| Coronary Stenosis | 3 | 2006 | 117 | 0.370 |
Why?
|
| Ischemia | 1 | 2013 | 391 | 0.350 |
Why?
|
| Erythropoietin | 2 | 2009 | 205 | 0.340 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2013 | 563 | 0.330 |
Why?
|
| Cardiomyopathies | 7 | 2021 | 610 | 0.320 |
Why?
|
| Weight Loss | 1 | 2013 | 627 | 0.320 |
Why?
|
| Chest Tubes | 1 | 2009 | 101 | 0.320 |
Why?
|
| Aortic Valve | 4 | 2020 | 581 | 0.320 |
Why?
|
| Peptide Fragments | 2 | 2013 | 1271 | 0.310 |
Why?
|
| Aortic Valve Stenosis | 1 | 2013 | 476 | 0.300 |
Why?
|
| Electric Countershock | 1 | 2007 | 71 | 0.290 |
Why?
|
| Pleural Effusion | 1 | 2009 | 201 | 0.290 |
Why?
|
| Aortic Valve Insufficiency | 4 | 2020 | 167 | 0.290 |
Why?
|
| Thromboembolism | 3 | 2020 | 155 | 0.290 |
Why?
|
| Shock, Cardiogenic | 4 | 2014 | 228 | 0.290 |
Why?
|
| Drainage | 1 | 2009 | 416 | 0.280 |
Why?
|
| Stents | 3 | 2013 | 1096 | 0.280 |
Why?
|
| Takayasu Arteritis | 1 | 2006 | 21 | 0.280 |
Why?
|
| Prosthesis Implantation | 5 | 2008 | 263 | 0.270 |
Why?
|
| Catheters, Indwelling | 1 | 2009 | 374 | 0.270 |
Why?
|
| Dobutamine | 1 | 2005 | 54 | 0.270 |
Why?
|
| Natriuretic Peptides | 1 | 2005 | 11 | 0.270 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2008 | 253 | 0.270 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2006 | 127 | 0.270 |
Why?
|
| Treatment Outcome | 19 | 2021 | 32848 | 0.260 |
Why?
|
| Transfusion Reaction | 1 | 2005 | 102 | 0.250 |
Why?
|
| Anemia | 2 | 2009 | 689 | 0.250 |
Why?
|
| Diastole | 1 | 2005 | 187 | 0.250 |
Why?
|
| Acute Kidney Injury | 2 | 2018 | 739 | 0.250 |
Why?
|
| Humans | 69 | 2021 | 261506 | 0.240 |
Why?
|
| Hospital Costs | 1 | 2005 | 228 | 0.240 |
Why?
|
| Male | 48 | 2021 | 123000 | 0.240 |
Why?
|
| Furans | 1 | 2004 | 104 | 0.230 |
Why?
|
| Cardiotonic Agents | 1 | 2005 | 151 | 0.230 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2004 | 177 | 0.230 |
Why?
|
| Equipment Design | 6 | 2018 | 1204 | 0.230 |
Why?
|
| West Nile Fever | 1 | 2005 | 151 | 0.220 |
Why?
|
| Severity of Illness Index | 6 | 2020 | 4320 | 0.220 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2003 | 66 | 0.220 |
Why?
|
| Middle Aged | 36 | 2020 | 86204 | 0.220 |
Why?
|
| Heart Ventricles | 5 | 2021 | 846 | 0.220 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 324 | 0.210 |
Why?
|
| Cardiomyopathy, Dilated | 5 | 2009 | 244 | 0.200 |
Why?
|
| Isoenzymes | 1 | 2004 | 614 | 0.200 |
Why?
|
| Heart Defects, Congenital | 1 | 2013 | 1697 | 0.200 |
Why?
|
| Chronic Disease | 5 | 2013 | 1819 | 0.200 |
Why?
|
| Time Factors | 14 | 2020 | 12926 | 0.190 |
Why?
|
| Female | 37 | 2021 | 141928 | 0.190 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2020 | 1237 | 0.190 |
Why?
|
| Warfarin | 2 | 2020 | 152 | 0.180 |
Why?
|
| Acute Disease | 4 | 2013 | 2422 | 0.180 |
Why?
|
| Plasmapheresis | 1 | 2019 | 61 | 0.180 |
Why?
|
| Aged | 25 | 2021 | 70117 | 0.180 |
Why?
|
| Equipment Failure | 3 | 2018 | 191 | 0.170 |
Why?
|
| Infusions, Intravenous | 4 | 2005 | 1382 | 0.160 |
Why?
|
| Clinical Trials as Topic | 2 | 2005 | 3719 | 0.160 |
Why?
|
| Heparin | 1 | 2019 | 360 | 0.150 |
Why?
|
| Doxorubicin | 1 | 2004 | 3005 | 0.140 |
Why?
|
| Retrospective Studies | 12 | 2021 | 37905 | 0.140 |
Why?
|
| Recombinant Proteins | 3 | 2013 | 2927 | 0.140 |
Why?
|
| Reoperation | 1 | 2020 | 1382 | 0.130 |
Why?
|
| Hirudins | 2 | 2013 | 65 | 0.130 |
Why?
|
| Patient Selection | 4 | 2010 | 2055 | 0.130 |
Why?
|
| Prosthesis Failure | 2 | 2013 | 206 | 0.130 |
Why?
|
| Air | 1 | 2014 | 63 | 0.120 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 846 | 0.120 |
Why?
|
| Multiple Organ Failure | 2 | 2006 | 177 | 0.120 |
Why?
|
| Cell-Derived Microparticles | 1 | 2014 | 41 | 0.120 |
Why?
|
| Transposition of Great Vessels | 1 | 2015 | 124 | 0.120 |
Why?
|
| Hemolysis | 1 | 2013 | 127 | 0.110 |
Why?
|
| Mesenteric Artery, Inferior | 1 | 2013 | 6 | 0.110 |
Why?
|
| Mesenteric Ischemia | 1 | 2013 | 12 | 0.110 |
Why?
|
| Stroke | 2 | 2020 | 1144 | 0.110 |
Why?
|
| Fontan Procedure | 1 | 2015 | 155 | 0.110 |
Why?
|
| Quality of Life | 5 | 2013 | 4532 | 0.110 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2013 | 71 | 0.110 |
Why?
|
| Blood Flow Velocity | 4 | 2008 | 475 | 0.110 |
Why?
|
| Risk Assessment | 6 | 2009 | 6869 | 0.110 |
Why?
|
| Follow-Up Studies | 9 | 2020 | 14889 | 0.100 |
Why?
|
| Radiography | 2 | 2014 | 1904 | 0.100 |
Why?
|
| Constriction, Pathologic | 1 | 2013 | 310 | 0.100 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 183 | 0.100 |
Why?
|
| Electrocardiography | 2 | 2010 | 1145 | 0.100 |
Why?
|
| Parotid Neoplasms | 1 | 2012 | 148 | 0.100 |
Why?
|
| Echocardiography | 3 | 2005 | 1182 | 0.100 |
Why?
|
| Anticoagulants | 4 | 2019 | 787 | 0.090 |
Why?
|
| Snakes | 1 | 2010 | 7 | 0.090 |
Why?
|
| Angina Pectoris | 1 | 2010 | 80 | 0.090 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2010 | 112 | 0.090 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2010 | 44 | 0.090 |
Why?
|
| Computer Simulation | 2 | 2005 | 1529 | 0.090 |
Why?
|
| Vascular Fistula | 1 | 2010 | 41 | 0.090 |
Why?
|
| Weight Gain | 1 | 2013 | 464 | 0.090 |
Why?
|
| Heart Neoplasms | 1 | 2012 | 214 | 0.090 |
Why?
|
| Swine | 1 | 2013 | 1541 | 0.080 |
Why?
|
| Postoperative Complications | 4 | 2020 | 5542 | 0.080 |
Why?
|
| Empyema, Pleural | 1 | 2009 | 48 | 0.080 |
Why?
|
| Vasodilation | 2 | 2008 | 205 | 0.080 |
Why?
|
| Coronary Circulation | 2 | 2010 | 253 | 0.080 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 4892 | 0.080 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2008 | 23 | 0.080 |
Why?
|
| Disease Progression | 4 | 2007 | 6682 | 0.080 |
Why?
|
| Extracorporeal Circulation | 1 | 2007 | 43 | 0.080 |
Why?
|
| Adult | 20 | 2020 | 77950 | 0.080 |
Why?
|
| Aged, 80 and over | 5 | 2013 | 29902 | 0.080 |
Why?
|
| Device Approval | 2 | 2004 | 21 | 0.080 |
Why?
|
| Equipment Safety | 2 | 2004 | 64 | 0.070 |
Why?
|
| Echocardiography, Stress | 2 | 2004 | 24 | 0.070 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2007 | 136 | 0.070 |
Why?
|
| Pilot Projects | 3 | 2014 | 2803 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2010 | 739 | 0.070 |
Why?
|
| Bundle-Branch Block | 1 | 2006 | 43 | 0.070 |
Why?
|
| Brachial Artery | 1 | 2006 | 38 | 0.070 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2006 | 21 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2010 | 451 | 0.070 |
Why?
|
| Myocardial Reperfusion | 1 | 2006 | 108 | 0.070 |
Why?
|
| Hematinics | 1 | 2006 | 109 | 0.070 |
Why?
|
| Pulsatile Flow | 1 | 2006 | 131 | 0.070 |
Why?
|
| Subclavian Artery | 1 | 2006 | 80 | 0.070 |
Why?
|
| Coronary Vessel Anomalies | 1 | 2010 | 300 | 0.070 |
Why?
|
| Sampling Studies | 1 | 2005 | 170 | 0.070 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2010 | 323 | 0.070 |
Why?
|
| Aortography | 1 | 2006 | 181 | 0.070 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2005 | 37 | 0.070 |
Why?
|
| Myocarditis | 1 | 2007 | 190 | 0.060 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2006 | 216 | 0.060 |
Why?
|
| Perfusion | 1 | 2006 | 293 | 0.060 |
Why?
|
| Hemoglobins | 1 | 2006 | 477 | 0.060 |
Why?
|
| Arteriovenous Malformations | 1 | 2005 | 70 | 0.060 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2005 | 57 | 0.060 |
Why?
|
| Equipment Failure Analysis | 1 | 2005 | 329 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2008 | 473 | 0.060 |
Why?
|
| Biomarkers | 2 | 2006 | 5047 | 0.060 |
Why?
|
| Drug Costs | 1 | 2005 | 144 | 0.060 |
Why?
|
| Cardiomyoplasty | 1 | 2003 | 7 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2009 | 9180 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2005 | 163 | 0.060 |
Why?
|
| Incidence | 3 | 2018 | 5673 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2010 | 998 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 215 | 0.060 |
Why?
|
| Blood Pressure | 2 | 2008 | 1467 | 0.060 |
Why?
|
| Myocardial Revascularization | 1 | 2004 | 134 | 0.060 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2003 | 68 | 0.060 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2004 | 200 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2004 | 409 | 0.060 |
Why?
|
| Research Design | 1 | 2010 | 1544 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2005 | 498 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2004 | 503 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 543 | 0.050 |
Why?
|
| Europe | 1 | 2004 | 649 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2005 | 340 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2010 | 1011 | 0.050 |
Why?
|
| Disease Models, Animal | 2 | 2013 | 7222 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2007 | 674 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 499 | 0.050 |
Why?
|
| United States | 4 | 2018 | 15433 | 0.050 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 483 | 0.050 |
Why?
|
| Inflammation Mediators | 1 | 2004 | 423 | 0.050 |
Why?
|
| Animals | 5 | 2013 | 59536 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2005 | 945 | 0.050 |
Why?
|
| Tachycardia, Ventricular | 1 | 2004 | 239 | 0.050 |
Why?
|
| Renal Dialysis | 2 | 2006 | 945 | 0.050 |
Why?
|
| Intestine, Small | 1 | 2005 | 499 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2006 | 1863 | 0.050 |
Why?
|
| Forecasting | 1 | 2003 | 694 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 2315 | 0.050 |
Why?
|
| Laser Therapy | 1 | 2005 | 411 | 0.050 |
Why?
|
| Waiting Lists | 3 | 2007 | 263 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2003 | 1313 | 0.040 |
Why?
|
| Young Adult | 3 | 2020 | 21445 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 3472 | 0.040 |
Why?
|
| Comorbidity | 1 | 2006 | 2352 | 0.040 |
Why?
|
| Prospective Studies | 4 | 2014 | 12873 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2007 | 2594 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2012 | 7702 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2015 | 1391 | 0.040 |
Why?
|
| Kidney | 2 | 2006 | 2146 | 0.040 |
Why?
|
| Hospitalization | 1 | 2006 | 2083 | 0.040 |
Why?
|
| Liver | 2 | 2006 | 2961 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 4938 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 2173 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2009 | 9244 | 0.040 |
Why?
|
| Stroke Volume | 2 | 2009 | 577 | 0.030 |
Why?
|
| Length of Stay | 1 | 2003 | 1900 | 0.030 |
Why?
|
| Risk Factors | 3 | 2014 | 17523 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2004 | 6009 | 0.030 |
Why?
|
| Survival Rate | 3 | 2018 | 12221 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 7789 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 2170 | 0.030 |
Why?
|
| Ventricular Septum | 1 | 2012 | 19 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 8865 | 0.030 |
Why?
|
| Prognosis | 2 | 2006 | 21713 | 0.020 |
Why?
|
| Proportional Hazards Models | 2 | 2009 | 4988 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 2009 | 159 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 83 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 118 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 323 | 0.020 |
Why?
|
| Endpoint Determination | 1 | 2008 | 176 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 866 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 3033 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2010 | 598 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2012 | 708 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2007 | 224 | 0.020 |
Why?
|
| Cause of Death | 1 | 2009 | 752 | 0.020 |
Why?
|
| Dipyridamole | 1 | 2006 | 33 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2010 | 769 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2010 | 834 | 0.020 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2005 | 26 | 0.020 |
Why?
|
| Rheology | 1 | 2005 | 55 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 276 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 2307 | 0.020 |
Why?
|
| Defibrillators, Implantable | 1 | 2008 | 221 | 0.020 |
Why?
|
| Dextrans | 1 | 2005 | 90 | 0.020 |
Why?
|
| Exercise Test | 1 | 2006 | 312 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2008 | 502 | 0.020 |
Why?
|
| Sheep | 1 | 2005 | 258 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 2139 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2010 | 1335 | 0.010 |
Why?
|
| Fluoroscopy | 1 | 2005 | 232 | 0.010 |
Why?
|
| Aspartate Aminotransferases | 1 | 2003 | 153 | 0.010 |
Why?
|
| Thoracotomy | 1 | 2005 | 220 | 0.010 |
Why?
|
| Adolescent | 2 | 2020 | 31252 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2005 | 303 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2005 | 829 | 0.010 |
Why?
|
| Alanine Transaminase | 1 | 2003 | 227 | 0.010 |
Why?
|
| Mice | 1 | 2004 | 34495 | 0.010 |
Why?
|
| Bilirubin | 1 | 2003 | 221 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 4298 | 0.010 |
Why?
|
| Dyspnea | 1 | 2005 | 416 | 0.010 |
Why?
|
| Autoantibodies | 1 | 2005 | 576 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 4971 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2003 | 291 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 531 | 0.010 |
Why?
|
| Device Removal | 1 | 2003 | 337 | 0.010 |
Why?
|
| Critical Illness | 1 | 2005 | 714 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 5377 | 0.010 |
Why?
|
| Kinetics | 1 | 2003 | 2049 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2009 | 6207 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 764 | 0.010 |
Why?
|
| Myocardium | 1 | 2003 | 1313 | 0.010 |
Why?
|
| Recurrence | 1 | 2004 | 4758 | 0.010 |
Why?
|
| Hypertension | 1 | 2005 | 1503 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2003 | 6100 | 0.010 |
Why?
|